Superworth

Anika Therapeutics EV/EBIT ANIK

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2012.

Today, Oct 23, 2026
n/m
an operating loss
Last meaningful
23.9×
May 2024
10-year median
15.7×
10-year range
5.2× to 117×
Peer median
14.6×

Anika Therapeutics has no meaningful EV/EBIT today: it made an operating loss of $5.1M over the last twelve months.

It was last meaningful in May 2024, at 23.9×.

On the days it had one over the last ten years, its median was 15.7×, from 5.2× in Mar 2020 to 117× in Mar 2022.

EV/EBIT over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
202423.9×21.2×32.4×
202327.4×19.4×42.1×
202279.6×18.5×117×
202122.8×22.8×52.9×
202039.7×5.2×39.7×
201915.3×10.8×24.8×
201814.0×8.7×20.6×
201713.1×9.8×14.1×
201610.7×8.8×12.7×
20159.9×6.5×11.7×
20148.0×7.6×18.3×
201314.1×6.2×14.2×
20126.1×6.1×11.2×

Against its peers

Companies in Medical - Instruments & Supplies nearest Anika Therapeutics' size, closest first, today.

CompanyEV/EBIT
ANIKAnika Therapeuticsn/m
INFUInfuSystem22.4×
UTMDUtah Medical Products6.0×
EMBCEmbecta6.7×
PDEXPro DEX16.0×
TCMDTactile Systems Technology13.3×
MDXGMimedx51.6×
MOVMovado11.8×
KEQUKewaunee Scientific7.2×
IRMDIradimed37.7×
STAAStaar Surgical57.7×
Peer median14.6×

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Anika Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.